Market Overview: Colorectal Cancer   26-page PDF document
$299.00

Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Colorectal Cancer (PDF)

PDF document 26 Pages

$299.00

Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF THIS PDF DOCUMENT

  1. Colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025
  2. Etiology and Pathophysiology
  3. Market Overview

HEALTHCARE PDF DESCRIPTION

This product (Market Overview: Colorectal Cancer) is a 26-page PDF document, which you can download immediately upon purchase.

The colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025 in the seven major pharmaceutical markets under study. Growth will be fueled by continued uptake of premium-priced therapies and the approval of six emerging therapies. In 2025, immune checkpoint inhibitors will hold an impressive 33% share of this market.

Two immune checkpoint inhibitors are expected to launch for colorectal cancer (Merck & Co.'s Keytruda [pembrolizumab] and Roche/Genentech/Chugai's Tecentriq [atezolizumab]), significantly contributing to the aforementioned market growth. Their combined major-market sales will total approximately $4.2 billion in 2025, driven largely by the two agents: approval in MSI-H and dMMR patient populations.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Colorectal Cancer PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

You must be logged in to contact the author.

Click here to log in Click here register

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"I have used FlevyPro for several business applications. It is a great complement to working with expensive consultants. The quality and effectiveness of the tools are of the highest standards."

– Moritz Bernhoerster, Global Sourcing Director at Fortune 500
 
"As a consulting firm, we had been creating subject matter training materials for our people and found the excellent materials on Flevy, which saved us 100's of hours of re-creating what already exists on the Flevy materials we purchased."

– Michael Evans, Managing Director at Newport LLC
 
"Flevy is our 'go to' resource for management material, at an affordable cost. The Flevy library is comprehensive and the content deep, and typically provides a great foundation for us to further develop and tailor our own service offer."

– Chris McCann, Founder at Resilient.World
 
"As a niche strategic consulting firm, Flevy and FlevyPro frameworks and documents are an on-going reference to help us structure our findings and recommendations to our clients as well as improve their clarity, strength, and visual power. For us, it is an invaluable resource to increase our impact and value."

– David Coloma, Consulting Area Manager at Cynertia Consulting
 
"My FlevyPro subscription provides me with the most popular frameworks and decks in demand in today’s market. They not only augment my existing consulting and coaching offerings and delivery, but also keep me abreast of the latest trends, inspire new products and service offerings for my practice, and educate me "

– Bill Branson, Founder at Strategic Business Architects
 
"As a young consulting firm, requests for input from clients vary and it's sometimes impossible to provide expert solutions across a broad spectrum of requirements. That was before I discovered Flevy.com.

Through subscription to this invaluable site of a plethora of topics that are key and crucial to consulting, I "

– Nishi Singh, Strategist and MD at NSP Consultants
 
"[Flevy] produces some great work that has been/continues to be of immense help not only to myself, but as I seek to provide professional services to my clients, it gives me a large "tool box" of resources that are critical to provide them with the quality of service and outcomes they are expecting."

– Royston Knowles, Executive with 50+ Years of Board Level Experience
 
"I have used Flevy services for a number of years and have never, ever been disappointed. As a matter of fact, David and his team continue, time after time, to impress me with their willingness to assist and in the real sense of the word. I have concluded in fact "

– Roberto Pelliccia, Senior Executive in International Hospitality


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Integrated Financial Model Value Chain Analysis

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.